DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients

Y.M. Jonkers, S.M.H. Claessen, A. Perren, A.M. Schmitt, L.J. Hofland, W.W. de Herder, R.R. de Krijger, A.A. Verhofstad, A.R. Hermus, J.A. Kummer, B. Skogseid, M. Volante, A.C. Voogd, F.C.S. Ramaekers, E.J.M. Speel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The clinical behavior of endocrine pancreatic tumors (EPTs) is difficult to predict in the absence of metastases or invasion to adjacent organs. Several markers have been indicated as potential predictors of metastatic disease, such as tumor size >= 2cm, Ki67 proliferative index 2%, cytokeratin (CK) 19 status, and recently in insulinomas, chromosomal instability (CIN). The goal of this study was to evaluate the value of these markers, and in particular of the CIN, to predict tumor recurrence or progression and tumor-specific death, using a series of 47 insulinomas and 24 noninsulinoma EPTs. From these EPT cases, a genomic profile has been generated and follow-up data have been obtained. The proliferative index has been determined in 68 tumors and a CK1 9 expression pattern in 50 tumors. Results are statistically analyzed using Kaplan-Meier plots and the log-rank statistic. General CIN, as well as specific chromosomal alterations such as 3p and 6q loss and 12q gain, turned out to be the most powerful indicators for poor tumor-free survival (P = 2% were reliable in predicting a poor tumor-f ree survival in noninsulinoma EPTs (P
Original languageEnglish
Pages (from-to)769-79
JournalEndocrine-Related Cancer
Volume14
Issue number3
DOIs
Publication statusPublished - 1 Jan 2007

Cite this

Jonkers, Y. M., Claessen, S. M. H., Perren, A., Schmitt, A. M., Hofland, L. J., de Herder, W. W., de Krijger, R. R., Verhofstad, A. A., Hermus, A. R., Kummer, J. A., Skogseid, B., Volante, M., Voogd, A. C., Ramaekers, F. C. S., & Speel, E. J. M. (2007). DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocrine-Related Cancer, 14(3), 769-79. https://doi.org/10.1677/ERC-07-0111